Type a term, then click a field below.

Search | advanced search

keepers

Type a term, then click a field below.

Search | simple search





13 subtopics

 

  • Cytochrome b6f Complex
  • Electron Transport Complex I
  • Electron Transport Complex IV
  • Fatty Acid Synthetase Complex
  • Glycine Decarboxylase Complex
  • Ketoglutarate Dehydrogenase Complex
  • Phosphoenolpyruvate Sugar Phosphotransferase System
  • Photosystem I Protein Complex
  • Photosystem II Protein Complex
  • Proteasome Endopeptidase Complex
  • Pyruvate Dehydrogenase Complex
  • Succinate Cytochrome c Oxidoreductase
  • Sucrase-Isomaltase Complex

Multienzyme ComplexesFollow by RSS 

You've reached a pubget topic page. Below are the latest papers on this topic, with subtopics on the left.

keywords > Macromolecular Substances > Multiprotein Complexes > Multienzyme Complexes

Latest papers

Secretory granule membrane protein recycles through multivesicular bodies.

Secretory granule membrane protein recycles through multivesicular bodies.

Secretory granule membrane protein recycles through multivesicular bodies.

Secretory granule membrane protein recycles through multivesicular bodies.

Secretory granule membrane protein recycles through multivesicular bodies.

Secretory granule membrane protein recycles through multivesicular bodies.

Secretory granule membrane protein recycles through multivesicular bodies.

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.

page 1 2 3 4 5 6 7 8 9 10 11 ...